08:57 AM EST - Oncolytics Biotech Inc : Announced that Germany's medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with modified FOLFIRINOX with or without atezolizumab (Tecentriq®) in newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients. Following a positive safety review by the independent Data Safety Monitoring Board, which recommended continuation, the PEI's approval allows Cohort 5 to progress to full enrollment. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $1.17.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACC&qmodStoryID=7842098247252852
